Following a non-profit report that higher rates of death were associated with Acadia Pharmaceuticals’ Nuplazid, Scott Gottlieb has made comments suggesting the FDA may return to take a second look at the drug.
FDA moots a return look at Acadia’s lead drug
Pharmafile
3 x gelezen









